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The threat of highly pathogenic avian influenza H5: Will H5N2 infections
occur in humans?To the Editor,
In early March 2012, animal health and quarantine officials
culled and then destroyed more than 54,000 chickens and
sterilized a farm in Changhua (in central Taiwan) due to an
outbreak of the highly pathogenic strain of avian influenza
(HPAI) H5N2.1 Because all of the news that has any
connection to avian influenza remains of great interest to the
public, this event caught the attention of the media and the
general population. Ultimately, the director of Taiwan’s
Bureau of Animal and Plant Health Inspection and Quarantine
resigned because of accusations of a cover-up.
The first case of avian influenza in humans was diagnosed
in Hong Kong in 1997.2 A total of 18 human cases and 6
deaths were reported, and all of the birds in the area markets
were destroyed. 3 Before this outbreak in Hong Kong, the
direct transmission of avian influenza to humans had never
been reported. It was believed that a barrier existed that pre-
vented the transmission of avian influenza to humans due to
differences between receptors. However, subsequent episodes
of avian influenza infecting the human population has been
reported with subtypes H7N7, H9N2, and H5N1.4 In 2003,
H5N1 avian influenza reemerged in humans and spread
throughout Southeast Asia, parts of Europe, and northern
Africa, sparing North and South America. The mortality rate
was estimated to be as high as 50e60%, vastly different from
that of seasonal influenza (estimated mortality rate of 0.1%).
However, the transmission efficacy of the H5N1 avian influ-
enza was poor and only a few cases of human-to-human
transmission were reported. The major route of transmission
was through direct contact between humans and birds instead
of via aerosol. However, recent studies have indicated that the
mortality rate of H5N1 avian influenza may have been over-
estimated, arising from a higher seroprevalence among
subclinical cases determined using meta-analysis. 5 Never-
theless, avian influenza poses a continuing threat to the human
population.
Regarding the evolution of H5N1 avian influenza, the
initial H5N1 progenitor reassortant (H5N1-PR1, A/Goose/
Guangdong/1/1996) was not a human pathogen.6 Only reas-
sortants H5N1-PR2 (1997) and H5N1-PR7 (since 2003) have
been associated with confirmed human cases. Having a firm1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.06.011grasp of the evolutionary patterns of H5N1 HPAIVs can help
to estimate the speed of emergence of avian influenza in
human cases.
In addition to the direct transmission of avian influenza to
humans, it is possible that the avian influenza genes incor-
porate and mix with the influenza genes from other species,
such as swine and human, resulting in genetic recombina-
tion. We had already experienced the emergence of reas-
sortant novel H1N1 influenza in 2009.7 Although the initial
2009 wave of influenza in Taiwan was mild,8 transmission
was not completely blocked by routine infectious disease
control procedures, and some atypical presentations could
occur in the future.9,10 Because there are not presently any
reported human cases of H5N2, the likely biological
behavior of this HPAI in humans is unclear and subject to
speculation. Based on the existence of multiple basic amino
acids in hemagglutinin, it is very likely that the H5N2 virus
will act more like the H5N1 virus. This is notwithstanding
the fact that the H5N2 virus will probably require some time
to evolve, so an imminent outbreak in humans is only
a remote possibility.
Nevertheless, several important steps should be initiated,
including the monitoring of personnel, animals on farms, and
migratory birds. In addition, an effective preparedness plan is
crucial, which should include an ongoing search for an
effective vaccine and the stockpiling of antiviral drugs and
personal protective devices. With accurate information and
ample preparedness, the status quo should be vigilance, not
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